Healthcare Industry News: Stereotactic
News Release - August 4, 2016
New Data Demonstrating TomoTherapy(R) System Adaptive Capabilities and Workhorse Reliability Presented at Leading Scientific Meeting for Medical PhysicistsSUNNYVALE, Calif., Aug. 4, 2016 -- (Healthcare Sales & Marketing Network) -- Accuray Incorporated (ARAY) announced today that new studies demonstrating the TomoTherapy® System's leading-edge adaptive therapy capabilities and value as a mainstream radiation therapy device were presented at the 58th Annual Meeting of the American Association of Physicists in Medicine (AAPM) held in Washington, DC, July 31 – August 4, 2016. More than 35 studies evaluating the system were shared during poster and oral presentations. The TomoTherapy System is used worldwide to treat a wide range of cancer cases, from the routine to complex, with extreme precision.
The AAPM studies validate the versatility and effectiveness of the TomoTherapy System and provide input to ongoing development. Research highlights include:
New software enables clinicians to confidently retreat recurrent cancer with radiation therapy.
Researchers at the Medical College of Wisconsin presented the first clinical results of a new automated retreatment planning process for the TomoTherapy System designed to minimize dose to previously irradiated organs at risk (OAR). Conventional retreatment plans created for representative patients previously treated using TomoHelical™ and later retreated near their original disease were compared to plans using the new process. Good quality registration of the initial treatment plan onto the CT used for the retreatment enabled additional planning constraints to be defined, resulting in minimized reirradiation of OARs without significantly affecting coverage of the planned treatment volume.
Accuray vision for the future: the most efficient and precise radiation therapy.
Researchers reported on progress made with managing target motion while leveraging the TomoTherapy System's unique daily imaging and helical delivery capabilities.
A team at the University of North Carolina, Chapel Hill, and Accuray, Incorporated, investigated real-time jaw/multileaf collimator (MLC) compensation approaches to minimize motion-induced variations in planned treatment volume coverage in TomoTherapy System Stereotactic body radiation therapy (SBRT) treatments. The team showed that for SBRT prostate and lung cases, if the motion pattern is known, a jaw and MLC compensation approach can minimize changes in target coverage and OAR sparing caused by motion.
Accuray researchers validated that a TomoTherapy System dose calculator can perform dose assessments for moving phantoms. The dose calculator accurately modeled the impact of moving the jaws and shifting MLC leaf patterns to compensate for motion during a TomoTherapy treatment delivery.
Study demonstrates TomoTherapy System performance remains consistent over the long-term.
The dosimetric stability of six TomoTherapy Systems was analyzed by researchers at the University of Wisconsin, Madison, to determine whether there were changes in performance over time and with system upgrades. Results showed that the output characteristics of the systems over a total of almost 10 years were extremely stable. For each system, results were consistent between the different measurement tools and techniques used in the evaluation, demonstrating dosimetric stability. Additionally, a system used for research purposes that operates at a higher dose rate performed as well as the systems used for clinical treatments.
"The use of radiation as part of cancer treatment is increasing, so the ability to deliver the correct amount of dose precisely to the tumor will become even more important," said Calvin Maurer, Ph.D., vice president and chief technology officer at Accuray. "The data presented at AAPM show that clinicians can be confident their TomoTherapy® System will deliver the precise radiation treatments they plan, day-to-day and year-by-year. Together with our customers we are working to make an excellent radiation therapy device even better, with enhancements designed to provide optimal outcomes for more patients."
For information on the TomoTherapy System, visit http://www.accuray.com/solutions/treatment-delivery/tomotherapy-treatment-delivery
Accuray Incorporated (ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient outcomes and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 28, 2015, the company's reports on Form 10-Q, filed on November 5, 2015 and February 1, 2016 and April 29, 2016, and the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsSwiss Medical Network Advances Cancer Care in Switzerland with Multi-System Agreement for Accuray Radiation Therapy Systems and RaySearch Oncology Software Systems
Accuray Launches Synchrony(R) Motion Tracking and Correction Technology for the Radixact(R) System
Phase 3 Randomized Trial Data Shows SBRT has Similar Acute Safety Profile to Conventional Radiation Therapy in Patients with Localized Prostate Cancer